Richard Hu
About Richard Hu
Richard Hu serves as the Director of Formulation Development at EyePoint Pharmaceuticals, where he has worked since 2021. He has extensive experience in drug product development, regulatory submissions, and implementing Quality by Design principles.
Work at EyePoint Pharmaceuticals
Richard Hu has served as the Director of Formulation Development at EyePoint Pharmaceuticals since 2021. In this role, he leads strategic initiatives aimed at enhancing functional processes within the Technical Operations department. His responsibilities include managing drug product development activities at external vendors to ensure compliance with regulatory and quality standards. Hu has also contributed to the preparation of sections for various regulatory filings, including IND, CTA, IMPD, NDA, and MAA submissions.
Previous Experience in the Pharmaceutical Industry
Before joining EyePoint Pharmaceuticals, Richard Hu held several positions in the pharmaceutical industry. He worked as Associate Director at Curis from 2015 to 2020, where he contributed to formulation development. Prior to that, he served as Scientist III at Alkermes from 2008 to 2012. He also worked at Cubist Pharmaceuticals as Scientist 2 (Formulation) from 2013 to 2015 and held the position of Director of CMC at Arsenal Medical for one year, from 2020 to 2021.
Education and Expertise
Richard Hu earned his Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Oklahoma, where he studied from 2000 to 2005. He also holds a Bachelor’s Degree in General Chemistry from Nanjing University, which he completed from 1994 to 1998. His educational background provides a strong foundation for his expertise in drug product development, particularly in implementing Quality by Design (QbD) principles and enhancing the bioavailability of poorly soluble compounds.
Technical Skills and Contributions
In his professional capacity, Richard Hu focuses on implementing Quality by Design (QbD) principles in drug product development. He emphasizes technical risk assessments and manufacturing control strategies to improve product quality. Hu has a proven track record in developing nano-suspensions and enhancing the bioavailability of poorly soluble compounds, showcasing his technical skills in formulation development.